knowledge -WSS

knowledge

author：hotspot 2025-09-28 21:04:22 - browse：3323

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

The benefits and risks of Eli Lilly’s treatment for Alzheimer’s disease were confirmed in detailed scientific disclosures Monday, paving the way for its full approval but leaving physicians with lingering questions about the medicine’s impact on patients as a new era in Alzheimer’s therapy unfolds.

The drug, called donanemab, showed a 35% slowing of Alzheimer’s disease progression relative to placebo in a clinical trial that enrolled 1,700 patients with early-stage disease. Numerically, that’s a modest, 3.3-point improvement on a 144-point survey, called the Integrated Alzheimer’s Disease Rating Scale, or iADRS, that combines measures of cognition and function, such as driving, managing finances, or carrying on conversations.

There was a similar benefit when donanemab’s efficacy was assessed using a more common measure of cognition called the Clinical Dementia Rating-Sum of Boxes, or CDR-SB. On that scale, the Lilly drug showed a 36% slowing of cognitive decline relative to placebo, or 0.68 points on an 18-point scale.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： What to do when lifesaving products contribute to climate change

WSS

Why health workers in Gaza are injured or die at high rates

Beam Therapeutics to lay off 20% of its staff, re

UnitedHealth’s Optum accused of antitrust violations in California

Diagnostic tests are hitting their mathematical limits

30 years of 'Listening to Prozac'

FDA gives detailed accounting of AI

hotspot

knowledge

hotspot

As demand for Covid shots wanes, Moderna seeks its next success

UnitedHealth’s board chair also owns a personal investment firm

United colonoscopy coverage change 'may cost lives,' doctors say

What don’t we know about an Alzheimer’s drug side effect?

Anesthesiologist group: stop taking Ozempic before surgery

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

Malaria cases in Florida and Texas: Here’s what you need to know

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

Anesthesiologist group: stop taking Ozempic before surgery

CEOs share strategies for surviving biotech slump

leisure time

U.K. Biobank has 500,000 peoples' genome sequences available

First Opinion Podcast: Long Covid needs a new approach

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

ReNAgade cuts staff seven months after raising $300 million

UnitedHealth’s board chair also owns a personal investment firm

Will Ozempic

knowledge

knowledge

focus

leisure time